NPM1 and acute myeloid leukemia: Categorization of cases according to the 2008 WHO classification revealed AML with recurrent genetic abnormalities as the largest subgroup (41.2%) including the two provisional entities AML with mutated NPM1 (25.3%) and AML with mutated CEBPA (4.2%), followed by AML not otherwise specified (30.5%), AML with MDS-related changes (24.5%), and therapy-related AML (3.8%) (Fig. 2).